NCT01113034View on ClinicalTrials.gov

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 22, 2011

Study Completion Date

August 22, 2011

Conditions
AsthmaBronchiectasis
Interventions
DRUG

DAS181 dry powder, formulation F02

10 mg delivered dose DAS181 in clear HPMC #3 Capsules

DRUG

Respitose ML006 (DMV-Fonterra)

Lactose monohydrate

Trial Locations (1)

20892

NIH Clinical Center, Bethesda

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Ansun Biopharma, Inc.

INDUSTRY